KAPA
Price:
$0.8998
Market Cap:
$18.67M
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Industry
Biotechnology
IPO Date
2024-09-16
Stock Exchange
AMEX
Ticker
KAPA
According to Kairos Pharma, Ltd.’s latest financial reports and current stock price. The company's current ROE is -79.19%. This represents a change of 295.12% compared to the average of -20.04% of the last 4 quarters.
The mean historical ROE of Kairos Pharma, Ltd. over the last ten years is 122.44%. The current -79.19% ROE has changed -164.67% with respect to the historical average. Over the past ten years (40 quarters), KAPA's ROE was at its highest in in the September 2023 quarter at 67.39%. The ROE was at its lowest in in the September 2024 quarter at -31.42%.
Average
122.44%
Median
89.06%
Minimum
-54.50%
Maximum
306.66%
Discovering the peaks and valleys of Kairos Pharma, Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 306.66%
Minimum Annual Increase = -162.50%
Minimum Annual ROE = -54.50%
| Year | ROE | Change |
|---|---|---|
| 2024 | -54.50% | -162.50% |
| 2023 | 87.20% | -2.09% |
| 2022 | 89.06% | -51.55% |
| 2021 | 183.80% | -40.06% |
The current ROE of Kairos Pharma, Ltd. (KAPA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
40.59%
5-year avg
122.44%
10-year avg
122.44%
Kairos Pharma, Ltd.’s ROE is greater than Lixte Biotechnology Holdings, Inc. (-308.56%), greater than Pelthos Therapeutics Inc. (-210.32%), greater than Lexaria Bioscience Corp. (-149.35%), less than CASI Pharmaceuticals, Inc. (358.32%), greater than Allarity Therapeutics, Inc. (-112.05%), less than Clearside Biomedical, Inc. (65.87%), greater than Cingulate Inc. (-842.45%), greater than BriaCell Therapeutics Corp. (-439.74%), greater than Entero Therapeutics, Inc. (-31.69%), greater than Pulmatrix, Inc. (-94.13%),
| Company | ROE | Market cap |
|---|---|---|
| -308.56% | $19.13M | |
| -210.32% | $16.92M | |
| -149.35% | $20.27M | |
| 358.32% | $15.40M | |
| -112.05% | $17.14M | |
| 65.87% | $4.97M | |
| -842.45% | $22.31M | |
| -439.74% | $22.93M | |
| -31.69% | $11.06M | |
| -94.13% | $14.91M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kairos Pharma, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kairos Pharma, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kairos Pharma, Ltd.'s ROE?
How is the ROE calculated for Kairos Pharma, Ltd. (KAPA)?
What is the highest ROE for Kairos Pharma, Ltd. (KAPA)?
What is the 3-year average ROE for Kairos Pharma, Ltd. (KAPA)?
What is the 5-year average ROE for Kairos Pharma, Ltd. (KAPA)?
How does the current ROE for Kairos Pharma, Ltd. (KAPA) compare to its historical average?